Angle Regulatory News (AGL)

ANGLE plc

("ANGLE" or "the Company")

APPOINTMENT OF SCIENTIFIC ADVISERS

ANGLE plc (AIM: AGL), the specialist medtech company, is delighted to announce that it has appointed two world-leading scientific advisers to help guide its Parsortix Non-Invasive Cancer Diagnostic technology to market. They are Professor Adrian Newland (who is not related to ANGLE's Chief Executive) and Professor Ashok Venkitaraman.

These scientific advisers provide crucial medical knowledge, market understanding and established relationships with key customers in their respective fields:

·; Prof Newland - diagnostics, haematology and the study of blood in disease detection and treatment;

·; Prof Venkitaraman - oncology, the detection of cancer and development of cancer drugs.

Prof Adrian Newland

Prof Newland is Professor of Haematology at Barts Health NHS Trust and Queen Mary University of London. He is Director of Pathology for the Trust and is Clinical Director of the North East London Cancer Network.

He was President of the British Society for Haematology in 1998-9 and was Chairman of the Science and Education Committee of the International Society for Haematology until 2009. He was awarded the British Society for Haematology Gold Medal in 2008. He was President of the Royal College of Pathologists from 2005 to 2008.

He chairs the National Blood Transfusion Committee and is pathology lead for NHS London. He is currently chair of the Diagnostic Assessment Programme for the National Institute for Health and Clinical Excellence (NICE), responsible for appraisal of new diagnostics and is a member of the NICE Sifting Group for cancer drugs.

Adrian has been a Member of the Scientific Advisory Panel of the Institute of Cancer Research from 1995 until 2003 and Chair of the London Cancer New Drugs Group since 2002 and also chairs the London Cancer Drugs Fund committee. He was a Member of the National Chemotherapy Advisory Group from 2003 to 2009. He has been a Member of the National Chemotherapy Implementation Group since 2010 and a Member of the Expert Reference Group on Cancer Care in London since 2009 and a current member of the national Cancer Outcomes Advisory Group and the Human Genome Strategy Group.

Prof Ashok Venkitaraman

Prof Venkitaraman holds the Ursula Zoellner Professorship of Cancer Research at the University of Cambridge, and is Director of the Medical Research Council's Cancer Cell Unit and Joint Director of the Medical Research Council Hutchison Cancer Research Centre. Ashok was a faculty member at the Medical Research Council's Laboratory of Molecular Biology in Cambridge, before appointment to the Zoellner Professorship in 1998.

Ashok's research has helped to elucidate the connections between chromosome instability and the genesis of epithelial cancers. He has been instrumental in establishing the Cambridge Molecular Therapeutics Programme, an initiative that links chemists, physicists, structural biologists, cancer biologists and clinicians at the University of Cambridge, with the aim to pioneer innovative new approaches for the discovery and early clinical development of next-generation medicines.

Ashok has been a member of the Scientific Advisory Boards of Astex Therapeutics Ltd, Cambridge Antibody Technology (AstraZeneca affiliate), Massachusetts General Hospital Cancer Center and currently chairs the Scientific Advisory Board of Sentinel Oncology Ltd. He has also been a John H Blaffer Lecturer at M D Anderson Cancer Center.

Ashok was elected a Fellow of the Academy of Medical Sciences, London, in 2001, and a Member of the European Molecular Biology Organization (EMBO) European Academy, Heidelberg, in 2004.

ANGLE's Founder and Chief Executive, Andrew Newland, commented:

"We are delighted to welcome two such distinguished experts to the ANGLE team. Their knowledge, expertise and profile will help us to position our Parsortix technology in the market and should be a great help in seeking early adoption of our new approach to the capture of circulating tumour cells."

For further information: